| HOME >> BIOLOGY >> TECHNOLOGY |
2007 2006
in thousands (unaudited)
Cash and investments* $94,058 $152,016
Total
assets 156,208 215,609
Total
liabilities 301,858 270,988
Total shareholders'
equity (145,650) (55,379)
* cash and investments include cash equivalents, restricted cash
equivalents and current and non-current investments
Any statements contained in this presentation that relate to future
plans, events or performance are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results, and the timing of events, to
differ materially from those described in the forward-looking statements.
These risks and uncertainties include, among others, those relating to our
ability to obtain financing and to form collaborative relationships,
uncertainty regarding potential future deterioration in the market for
auction rate securities which could result in additional permanent
impairment charges, our ability to develop and market diagnostic products,
the level of third party reimbursement for our products, risks related to
preclinical and clinical development of pharmaceutical products, including
the identification of compounds and the completion of clinical trials, the
effect of government regulation and the regulatory approval processes,
market acceptance, our ability to obtain and protect intellectual property
rights for our products, dependence on collaborative relationships, the
effect of competitive products, industry trends and other risks identified
in deCODE's filings with the Securities and Exchange Commission, in
'/>"/>
| SOURCE deCODE genetics Copyright©2008 PR Newswire. All rights reserved |